Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
暂无分享,去创建一个
G. Talbot | G. Donowitz | M. Brandon | J. Salisbury | C. Harman | D. Tipping | A. Urick | George H. Talbot | Milan L. Brandon | John P. Salisbury | Colleen P. Harman | Diane Tipping | Ann E. Urick
[1] Sheldon P Stone,et al. Community-acquired pneumonia , 1998, The Lancet.
[2] P. Saikku,et al. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. , 1996, Chest.
[3] R. Peeling,et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. , 1996, The American journal of medicine.
[4] G. Talbot,et al. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. , 1996, The Journal of antimicrobial chemotherapy.
[5] D. Honeybourne,et al. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. , 1996, The Journal of antimicrobial chemotherapy.
[6] H. Portier,et al. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group. , 1996, The Journal of antimicrobial chemotherapy.
[7] W. Wijnands,et al. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. , 1996, The Journal of antimicrobial chemotherapy.
[8] H. Lode,et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. , 1995, The European respiratory journal.
[9] G. Mccracken,et al. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. , 1994, The New England journal of medicine.
[10] F. Tenover,et al. Emergence of drug-resistant pneumococcal infections in the United States. , 1994, JAMA.
[11] M. Kaku,et al. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae , 1994, Antimicrobial Agents and Chemotherapy.
[12] V L Yu,et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. , 1993 .
[13] D. Barnes. Microbial etiology of acute pneumonia in hospitalized patients. , 1993, Chest.
[14] Y. Niki,et al. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents , 1993, Antimicrobial Agents and Chemotherapy.
[15] L. Reller,et al. Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group. , 1992, Diagnostic microbiology and infectious disease.
[16] N. Klein. Fluoroquinolones in respiratory infections. , 1991, Seminars in respiratory infections.
[17] A. Barry,et al. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin , 1991, Antimicrobial Agents and Chemotherapy.
[18] W. Kapoor,et al. New and Emerging Etiologies for Community‐Acquired Pneumonia with Implications for Therapy: A Prospective Multicenter Study of 359 Cases , 1990, Medicine.
[19] D. Kaiser,et al. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. , 1989, Thorax.
[20] T. Marrie,et al. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. , 1989, Reviews of infectious diseases.
[21] T. Marrie,et al. Community‐Acquired Pneumonia Requiring Hospitalization , 1985, Journal of the American Geriatrics Society.
[22] W. Marine,et al. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. , 1971, Archives of internal medicine.
[23] A. Malmborg,et al. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens. , 1993, Chemotherapy.
[24] J T Macfarlane,et al. Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias. , 1987, British journal of diseases of the chest.